AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295
Debt
Debt-to-Equity Ratio0.01
Current Ratio16.19
Quick Ratio16.19
Price-To-Earnings
Trailing P/E Ratio-55.05
Forward P/E Ratio-33.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales207.03
Cash FlowN/A
Price / CashN/A
Book Value$13.09 per share
Price / Book6.58
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-30,070,000.00
Net MarginsN/A
Return on Equity-18.07%
Return on Assets-16.66%
Miscellaneous
Employees60
Outstanding Shares24,040,000
Market Cap$2.01 billion
AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions
What is AnaptysBio's stock symbol?
AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."
How were AnaptysBio's earnings last quarter?
AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.70) by $0.13. View AnaptysBio's Earnings History.
When is AnaptysBio's next earnings date?
What price target have analysts set for ANAB?
8 brokerages have issued twelve-month price targets for AnaptysBio's stock. Their predictions range from $84.00 to $162.00. On average, they anticipate AnaptysBio's stock price to reach $133.8750 in the next year. This suggests a possible upside of 55.5% from the stock's current price. View Analyst Price Targets for AnaptysBio.
What is the consensus analysts' recommendation for AnaptysBio?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AnaptysBio.
Who are some of AnaptysBio's key competitors?
Some companies that are related to AnaptysBio include Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO) and Ultragenyx Pharmaceutical (RARE).
Who are AnaptysBio's key executives?
AnaptysBio's management team includes the folowing people:
- Mr. Hamza Suria, Pres, CEO & Director (Age 42)
- Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 43)
- Prof. Marco Londei, Chief Medical Officer (Age 61)
- Dr. Margaret Marino Ph.D., VP of Project Management
When did AnaptysBio IPO?
(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has AnaptysBio been receiving favorable news coverage?
Media coverage about ANAB stock has trended positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AnaptysBio earned a daily sentiment score of 0.33 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 51.79 out of 100, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View Recent Headlines for AnaptysBio.
Who are AnaptysBio's major shareholders?
AnaptysBio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Janus Henderson Group PLC (12.04%), Frazier Management LLC (9.64%), BlackRock Inc. (6.23%), OppenheimerFunds Inc. (4.58%) and Redmile Group LLC (2.16%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.
Which institutional investors are selling AnaptysBio stock?
ANAB stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, FMR LLC, Baker BROS. Advisors LP, Senzar Asset Management LLC, Alps Advisors Inc., Redmile Group LLC, California Public Employees Retirement System and TD Asset Management Inc.. Company insiders that have sold AnaptysBio company stock in the last year include Holdings A/S Novo and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.
Which institutional investors are buying AnaptysBio stock?
ANAB stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Partner Fund Management L.P., OppenheimerFunds Inc., Federated Investors Inc. PA, BlackRock Inc., Asymmetry Capital Management L.P., Los Angeles Capital Management & Equity Research Inc. and First Trust Advisors LP. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.
How do I buy shares of AnaptysBio?
Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AnaptysBio's stock price today?
One share of ANAB stock can currently be purchased for approximately $86.12.
How big of a company is AnaptysBio?
AnaptysBio has a market capitalization of $2.01 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.
How can I contact AnaptysBio?
AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]
MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
